ClinicalTrials.gg
CompletedNCT04667377Updated Nov 2, 2023Results posted

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

A Phase 2 interventional study of BI 456906 and Placebo in Obesity, sponsored by Boehringer Ingelheim. Completed at 43 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-11-02.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
387
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Enrollment
6th of 22
387 · median 121
Started
2021
the only one that year
Phase 2
Only one
of the 22
Registered
2nd of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 6th largest by enrollment, is the only one that started in 2021, is the only one in phase 2, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to adults, aged 18 to 75 years, with overweight or obesity. People with body mass index (BMI) of 27 or higher to join the study. People who have diabetes cannot participate. The purpose of this study is to find out whether a medicine called BI 456906 helps people lose weight.

Participants are put into 5 groups by chance. 4 groups get different doses of BI 456906. The fifth group gets placebo. Participants get BI 456906 or placebo as injections under the skin once a week. Placebo injections look like BI 456906 injections but do not contain any medicine.

Participants are in the study for about a year. During this time, there are about 20 in-person visits to the study site. At the study site visits, doctors measure participants' body weight. Results are compared between the BI 456906 groups and the placebo group. The doctors also regularly check the general health of the participants.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult ≥ 18 years and \< 75 years of age at screening
  • Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial.
  • Obesity or Overweight defined as ≥27 kg/m2 at screening
  • A minimum absolute body weight of 70 kg for females and 80 kg for males at screening
  • Male or female participants. Women of (WOCBP)1 must be willing and able to use two forms of effective where at least one form is highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
  • Patients must have undergone at least one previous unsuccessful nonsurgical weight-loss attempt per investigator's judgement

Exclusion criteria

Exclusion criteria:

  • Body weight change of over +/- 5% or more in the past 12 weeks prior to randomization. There must be documentation of weight in the past 12 weeks before randomization.
  • Obesity induced by an endocrinologic disorder (i.e. Cushing Syndrome, hypogonadism, growh hormone deficiency. However, well controlled hypothyroidism, polycystic ovarian disease are still allowed)
  • A ≥ 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus
  • Exposure to Glucagon like peptide-1 receptor agonist (GLP-1Ra) based therapies within three months prior to screening
  • Any suicidal behaviour in the past 2 years, any suicidal ideation of type 4 or 5 in the Columbia-Suicide Severity Rating Scale (CSSRS) within 3 months before screening, or during screening period
  • History of major depressive disorder within 2 years before randomization
  • Major depressive symptoms (defined as a screening Patient Health Questionnaire-9 [PHQ-9] score ≥15) at screening and/or during screening period
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders at screening
  • Chronic or relevant acute infections (including but not limited to respiratory tract infections, urinary tract infection, bladder infection, enterocolitis, abscess, tuberculosis, meningitis, influenza, Epstein-Barr virus, /AIDS, and or C, and severe acute respiratory syndrome coronavirus type 19 (SARS CoV-2) (as confirmed by Polychain reaction (PCR) test)), within 2 weeks from screening or during screening.
  • Further exclusion criteria apply
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
387 participants (actual)

Study arms

  • Experimental
    0.6 mg BI 456906

    Drug: BI 456906

  • Placebo comparator
    Placebo group

    Drug: Placebo

  • Experimental
    2.4 mg BI456906

    Drug: BI 456906

  • Experimental
    3.6 mg BI 456906

    Drug: BI 456906

  • Experimental
    4.8 mg BI 456906

    Drug: BI 456906

Interventions

  • BI 456906

    Also known as: Survodutide

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Percentage Change in Body Weight From Baseline to Week 46

    Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".

    Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

Secondary outcomes

  1. Weight Loss of ≥ 5% of Baseline Weight at Week 46

    Weight loss of greater than or equal to 5 percent (≥5%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥5% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.

    Time frame: At baseline and at Week 46.

  2. Weight Loss of ≥ 10% of Baseline Weight at Week 46

    Weight loss of greater than or equal to 10 percent (≥10%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥10% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.

    Time frame: At baseline and at Week 46.

  3. Weight Loss of ≥ 15% of Baseline Weight at Week 46

    Weight loss of greater than or equal to 15 percent (≥15%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥15% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.

    Time frame: At baseline and at Week 46.

  4. Absolute Change in Body Weight From Baseline to Week 46

    Absolute change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

    Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

  5. Absolute Change in Waist Circumference From Baseline to Week 46

    Absolute change in waist circumference from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline waist circumference as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 6, 12, 18, 24, 32, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

    Time frame: Baseline, Week 6, 12, 18, 24, 32, 40, and 46.

  6. Absolute Change in Systolic Blood Pressure From Baseline to Week 46

    Absolute change in systolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline systolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

    Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

  7. Absolute Change in Diastolic Blood Pressure From Baseline to Week 46

    Absolute change in diastolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline diastolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

    Time frame: Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

07

Results

Posted Nov 2, 2023

Participant flow

This was a randomised, double-blinded, parallel-design, placebo-controlled, multi-national, and multi-centre study with four different BI 456906 maintenance doses (ranging from 0.6 mg/week to 4.8 mg/week) in patients with obesity or overweight (body mass index (BMI) \>=27 kg/m\^2), and without diabetes mellitus.

Dose Escalation Period
Participant flow — Dose Escalation Period
Milestone0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Started7878777777
Treated during dose escalation period7778777777
Completed5560595557
Not completed2318182220
Withdrew: Other not specified below33213
Withdrew: Protocol violation22021
Withdrew: Burden of study procedures21115
Withdrew: Change of residence00100
Withdrew: Perceived lack of efficacy00006
Withdrew: Adverse event91012173
Withdrew: Adverse event: covid-infection41210
Withdrew: Not treated10000
Withdrew: Withdrawal by subject20002
Withdrew: Lost to follow-up01000
Maintenance Period
Participant flow — Maintenance Period
Milestone0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Started5560595557
Completed4745484746
Not completed81511811
Withdrew: Perceived lack of efficacy02101
Withdrew: Adverse event28541
Withdrew: Adverse event: covid infection01000
Withdrew: Covid-related00110
Withdrew: Protocol violation10001
Withdrew: Burden of study procedures12010
Withdrew: Change of residence01001
Withdrew: Missing10000
Withdrew: Other than listed above20326
Withdrew: Withdrawal by subject01000
Withdrew: Lost to follow-up10101

Outcome measures

PrimaryPercentage Change in Body Weight From Baseline to Week 46

Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".

Time frame:
Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Reported as:
Least squares mean · Percentage change
Percentage Change in Body Weight From Baseline to Week 46
Percentage change0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Percentage Change in Body Weight From Baseline to Week 46-6.19 ± 1.07-12.51 ± 1.01-13.22 ± 1.04-14.94 ± 1.01-2.82 ± 1.06
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs 2.4 mg BI 456906 - Planned Maintenance Treatment vs 3.6 mg BI 456906 - Planned Maintenance Treatment vs 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · MCP-Mod - Linear model fit · p = <0.0001 (P-value is adjusted for multiplicity.)
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs 2.4 mg BI 456906 - Planned Maintenance Treatment vs 3.6 mg BI 456906 - Planned Maintenance Treatment vs 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · MCP-Mod - Exponential model fit · p = <0.0001 (P-value is adjusted for multiplicity.)Model Assumption: 50% of maximum effect achieved at dose 3.6 mg.
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs 2.4 mg BI 456906 - Planned Maintenance Treatment vs 3.6 mg BI 456906 - Planned Maintenance Treatment vs 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · MCP-Mod - Emax1 model fit · p = <0.0001 (P-value is adjusted for multiplicity.)Model Assumption: 90% of maximum effect achieved at dose 4.8 mg.
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs 2.4 mg BI 456906 - Planned Maintenance Treatment vs 3.6 mg BI 456906 - Planned Maintenance Treatment vs 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · MCP-Mod - Emax2 model fit · p = <0.0001 (P-value is adjusted for multiplicity.)Model Assumption: 70% of maximum effect achieved at dose 4.8 mg.
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs 2.4 mg BI 456906 - Planned Maintenance Treatment vs 3.6 mg BI 456906 - Planned Maintenance Treatment vs 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · MCP-Mod - Sigmoid Emax model fit · p = <0.0001 (P-value is adjusted for multiplicity.)Model Assumption: 50% of maximum effect achieved at dose 2.4 mg, 90% of maximum effect achieved at dose 4.8 mg.
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Mixed Models Analysis · p = 0.0257 (P-value is considered nominal.) · Difference of adjusted means: -3.37 · 95% CI -6.33 to -0.41Difference was calculated as BI 456906 - placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -9.69 · 95% CI -12.57 to -6.81Difference was calculated as BI 456906 - placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -10.40 · 95% CI -13.32 to -7.49Difference was calculated as BI 456906 - placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -12.12 · 95% CI -15.00 to -9.24Difference was calculated as BI 456906 - placebo.
SecondaryWeight Loss of ≥ 5% of Baseline Weight at Week 46

Weight loss of greater than or equal to 5 percent (≥5%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥5% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.

Time frame:
At baseline and at Week 46.
Reported as:
Number · Percentage of participants
Weight Loss of ≥ 5% of Baseline Weight at Week 46
Percentage of participants0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Weight Loss of ≥ 5% of Baseline Weight at Week 4660.781.082.082.825.9
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Regression, Logistic · p = 0.0015 (P-value is considered nominal.) · Odds ratio (or): 3.28 · 95% CI 1.57 to 6.84Odds ratio is calculated as BI 456906 / Placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 8.83 · 95% CI 4.00 to 19.46Odds ratio is calculated as BI 456906 / Placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 7.48 · 95% CI 3.41 to 16.41Odds ratio is calculated as BI 456906 / Placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 10.77 · 95% CI 4.77 to 24.31Odds ratio is calculated as BI 456906 / Placebo.
SecondaryWeight Loss of ≥ 10% of Baseline Weight at Week 46

Weight loss of greater than or equal to 10 percent (≥10%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥10% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.

Time frame:
At baseline and at Week 46.
Reported as:
Number · Percentage of participants
Weight Loss of ≥ 10% of Baseline Weight at Week 46
Percentage of participants0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Weight Loss of ≥ 10% of Baseline Weight at Week 4633.965.565.668.811.1
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Regression, Logistic · p = 0.0120 (P-value is considered nominal.) · Odds ratio (or): 3.22 · 95% CI 1.29 to 8.02Odds ratio is calculated as BI 456906 / Placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 10.62 · 95% CI 4.36 to 25.86Odds ratio is calculated as BI 456906 / Placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 9.78 · 95% CI 4.02 to 23.79Odds ratio is calculated as BI 456906 / Placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 14.50 · 95% CI 5.91 to 35.55Odds ratio is calculated as BI 456906 / Placebo.
SecondaryWeight Loss of ≥ 15% of Baseline Weight at Week 46

Weight loss of greater than or equal to 15 percent (≥15%) of baseline weight at Week 46 (yes/no), reported as percentage of participants who achieved a weight loss of ≥15% of baseline weight at Week 46. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. Percentages were rounded to one decimal place.

Time frame:
At baseline and at Week 46.
Reported as:
Number · Percentage of particpants
Weight Loss of ≥ 15% of Baseline Weight at Week 46
Percentage of particpants0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Weight Loss of ≥ 15% of Baseline Weight at Week 4612.537.945.954.75.6
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Regression, Logistic · p = 0.2654 (P-value is considered nominal.) · Odds ratio (or): 2.13 · 95% CI 0.56 to 8.02Odds ratio is calculated as BI 456906 / Placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = 0.0002 (P-value is considered nominal.) · Odds ratio (or): 9.47 · 95% CI 2.89 to 30.95Odds ratio is calculated as BI 456906 / Placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 11.79 · 95% CI 3.62 to 38.36Odds ratio is calculated as BI 456906 / Placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Regression, Logistic · p = <.0001 (P-value is considered nominal.) · Odds ratio (or): 21.02 · 95% CI 6.47 to 68.28Odds ratio is calculated as BI 456906 / Placebo.
SecondaryAbsolute Change in Body Weight From Baseline to Week 46

Absolute change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

Time frame:
Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Reported as:
Least squares mean · Kilogram (kg)
Absolute Change in Body Weight From Baseline to Week 46
Kilogram (kg)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Absolute Change in Body Weight From Baseline to Week 46-7.21 ± 1.06-14.75 ± 1.03-15.64 ± 1.04-18.47 ± 1.04-2.68 ± 1.04
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Mixed Models Analysis · p = 0.0025 (P-value is considered nominal.) · Difference of adjusted means: -4.53 · 95% CI -7.44 to -1.61Difference was calculated as BI 456906 - placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -12.07 · 95% CI -14.94 to -9.19Difference was calculated as BI 456906 - placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -12.96 · 95% CI -15.85 to -10.07Difference was calculated as BI 456906 - placebo at week 46.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -15.78 · 95% CI -18.67 to -12.90Difference was calculated as BI 456906 - placebo at week 46.
SecondaryAbsolute Change in Waist Circumference From Baseline to Week 46

Absolute change in waist circumference from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline waist circumference as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 6, 12, 18, 24, 32, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

Time frame:
Baseline, Week 6, 12, 18, 24, 32, 40, and 46.
Reported as:
Least squares mean · Centimeter (cm)
Absolute Change in Waist Circumference From Baseline to Week 46
Centimeter (cm)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Absolute Change in Waist Circumference From Baseline to Week 46-8.32 ± 1.22-14.99 ± 1.21-14.96 ± 1.19-16.01 ± 1.19-3.96 ± 1.20
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Mixed Models Analysis · p = 0.0116 (P-value is considered nominal.) · Difference of adjusted means: -4.36 · 95% CI -7.74 to -0.98Difference was calculated as BI 456906 - placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -11.03 · 95% CI -14.39 to -7.66Difference was calculated as BI 456906 - placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -11.00 · 95% CI -14.33 to -7.67Difference was calculated as BI 456906 - placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0001 (P-value is considered nominal.) · Difference of adjusted means: -12.05 · 95% CI -15.39 to -8.71Difference was calculated as BI 456906 - placebo.
SecondaryAbsolute Change in Systolic Blood Pressure From Baseline to Week 46

Absolute change in systolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline systolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

Time frame:
Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Reported as:
Least squares mean · Millimeter of mercury (mmHg)
Absolute Change in Systolic Blood Pressure From Baseline to Week 46
Millimeter of mercury (mmHg)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Absolute Change in Systolic Blood Pressure From Baseline to Week 46-6.19 ± 1.47-8.08 ± 1.48-8.66 ± 1.44-8.62 ± 1.46-2.46 ± 1.46
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Mixed Models Analysis · p = 0.0733 (P-value is considered nominal.) · Difference of adjusted means: -3.73 · 95% CI -7.82 to 0.35Difference was calculated as BI 456906 - placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = <.0072 (P-value is considered nominal.) · Difference of adjusted means: -5.62 · 95% CI -9.71 to 1.53Difference was calculated as BI 456906 - placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = 0.0027 (P-value is considered nominal.) · Difference of adjusted means: -6.20 · 95% CI -10.23 to -2.17Difference was calculated as BI 456906 - placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = 0.0033 (P-value is considered nominal.) · Difference of adjusted means: -6.16 · 95% CI -10.25 to -2.06Difference was calculated as BI 456906 - placebo.
SecondaryAbsolute Change in Diastolic Blood Pressure From Baseline to Week 46

Absolute change in diastolic blood pressure from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline diastolic blood pressure as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures and an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. MMRM analysis was performed on the FAS, using planned maintenance treatment (dose assigned at randomisation) and including only on-treatment data, regardless of whether early treatment discontinuation was COVID-19 related.

Time frame:
Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Reported as:
Least squares mean · Millimeter of mercury (mmHg)
Absolute Change in Diastolic Blood Pressure From Baseline to Week 46
Millimeter of mercury (mmHg)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlacebo
Absolute Change in Diastolic Blood Pressure From Baseline to Week 46-3.31 ± 0.90-4.36 ± 0.90-4.31 ± 0.87-4.80 ± 0.89-1.87 ± 0.89
Statistical analysis
  • 0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation) vs Placebo · Mixed Models Analysis · p = 0.2569 (P-value is considered nominal.) · Difference of adjusted means: -1.44 · 95% CI -3.92 to 1.05Difference was calculated as BI 456906 - placebo.
  • 2.4 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = 0.0495 (P-value is considered nominal.) · Difference of adjusted means: -2.49 · 95% CI -4.97 to -0.00Difference was calculated as BI 456906 - placebo.
  • 3.6 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = 0.0506 (P-value is considered nominal.) · Difference of adjusted means: -2.44 · 95% CI -4.90 to 0.01Difference was calculated as BI 456906 -placebo.
  • 4.8 mg BI 456906 - Planned Maintenance Treatment vs Placebo · Mixed Models Analysis · p = 0.0202 (P-value is considered nominal.) · Difference of adjusted means: -2.93 · 95% CI -5.40 to -0.46Difference was calculated as BI 456906 - placebo.

Adverse events

Collected over From first drug administration until last drug administration, plus 28 days residual effect period (REP), up to 360 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
0.6 mg BI 456906 - Actual Maintenance Treatment0/92 (0%)2/92 (2.2%)70/92 (76.1%)
2.4 mg BI 456906 - Actual Maintenance Treatment0/92 (0%)3/92 (3.3%)79/92 (85.9%)
3.6 mg BI 456906 - Actual Maintenance Treatment0/71 (0%)4/71 (5.6%)64/71 (90.1%)
4.8 mg BI 456906 - Actual Maintenance Treatment0/54 (0%)4/54 (7.4%)46/54 (85.2%)
Placebo0/77 (0%)5/77 (6.5%)48/77 (62.3%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
Event0.6 mg BI 456906 - Actual Maintenance Treatment2.4 mg BI 456906 - Actual Maintenance Treatment3.6 mg BI 456906 - Actual Maintenance Treatment4.8 mg BI 456906 - Actual Maintenance TreatmentPlacebo
CholecystitisHepatobiliary disorders0/920/920/711/540/77
CholelithiasisHepatobiliary disorders0/920/920/711/540/77
TonsillitisInfections and infestations0/920/920/711/540/77
Glioblastoma multiformeNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/920/920/711/540/77
Uterine prolapseReproductive system and breast disorders0/920/920/711/540/77
Incisional herniaInjury, poisoning and procedural complications0/920/921/710/540/77
Wrist fractureInjury, poisoning and procedural complications0/920/921/710/540/77
Intraductal proliferative breast lesionNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/920/921/710/540/77
AngioedemaSkin and subcutaneous tissue disorders0/920/921/710/540/77
COVID-19 pneumoniaInfections and infestations0/920/920/710/541/77
Most frequent other events
Showing 10 of 24
Most frequent other events
Event0.6 mg BI 456906 - Actual Maintenance Treatment2.4 mg BI 456906 - Actual Maintenance Treatment3.6 mg BI 456906 - Actual Maintenance Treatment4.8 mg BI 456906 - Actual Maintenance TreatmentPlacebo
NauseaGastrointestinal disorders36/9260/9245/7132/5415/77
VomitingGastrointestinal disorders13/9228/9228/7113/544/77
ConstipationGastrointestinal disorders11/9219/9222/7113/544/77
DiarrhoeaGastrointestinal disorders22/9221/9217/719/548/77
COVID-19Infections and infestations18/9211/9217/717/5417/77
Decreased appetiteMetabolism and nutrition disorders11/9210/9216/713/541/77
FatigueGeneral disorders6/925/9213/715/546/77
Gastrooesophageal reflux diseaseGastrointestinal disorders2/927/9210/715/543/77
DizzinessNervous system disorders1/928/9210/714/542/77
HeadacheNervous system disorders8/927/9210/715/546/77

Baseline characteristics

Full analysis set (FAS): All randomised participants who received at least one dose of trial medication and who had analysable data for at least one efficacy endpoint, using planned maintenance treatment.

Age, Continuous
Age, Continuous(Years)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlaceboTotal
Mean48.6 ± 12.649.0 ± 13.150.3 ± 11.847.6 ± 13.550.0 ± 13.548.9 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlaceboTotal
Female5154515353262
Male2624252324122
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlaceboTotal
Hispanic or Latino3126517
Not Hispanic or Latino7477747072367
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlaceboTotal
American Indian or Alaska Native000101
Asian8997740
Native Hawaiian or Other Pacific Islander000112
Black or African American10838837
White5960635960301
More than one race011013
Unknown or Not Reported000000
Body weight at baseline
Body weight at baseline(Kilogram (kg))0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)2.4 mg BI 456906 - Planned Maintenance Treatment3.6 mg BI 456906 - Planned Maintenance Treatment4.8 mg BI 456906 - Planned Maintenance TreatmentPlaceboTotal
Mean106.98 ± 18.71106.57 ± 22.97104.68 ± 19.63105.86 ± 17.39104.32 ± 22.95105.68 ± 20.39
08

Study locations

43 sites
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Valley Weight Loss Clinic
    Fargo, North Dakota 58104, United States
  • Velocity Clinical Research, Inc.
    Cleveland, Ohio 44122, United States
  • TLM Medical Services, LLC
    Columbia, South Carolina 29204, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Washington Center for Weight Management and Research, Inc.
    Arlington, Virginia 22206, United States
  • Allegiance Research Specialists
    Wauwatosa, Wisconsin 53226, United States
  • The Boden Initiative
    Camperdown, New South Wales 2006, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
  • Eastern Clinical Research Unit
    East Ringwood, Victoria 3135, Australia
  • Austin Health
    Heidelberg, Victoria 3081, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • Joanne F Liutkus Medicine Professional Corporation
    Cambridge, Ontario N3H 4L5, Canada
  • Bluewater Clinical Research
    Sarnia, Ontario N7T 4X3, Canada
  • Canadian Phase Onward Inc.
    Toronto, Ontario M3J 0K2, Canada
  • LMC Clinical Research Inc. (Bayview)
    Toronto, Ontario M4G 3E8, Canada
  • Recherche GCP Research
    Montreal, Quebec H1M 1B1, Canada
  • Beijing Chao-Yang Hospital
    Beijing, 100020, China
  • Beijing Luhe Hospital Capital Medical University
    Beijing, 101199, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • Wuhan Union Hospital
    Wuhan, 430022, China
  • Klinische Forschung Berlin GbR
    Berlin, 10787, Germany
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 01307, Germany
  • Seoul National University Bundang Hospital
    Seongnam, 13620, Korea, Republic of
  • Kyung Hee University Hospital at Gangdong
    Seoul, 05278, Korea, Republic of
  • The Catholic University of Korea, Yeouido St.Mary's Hospital
    Seoul, 07345, Korea, Republic of
  • EB Flevoresearch
    Almere, 1311 RL, Netherlands
  • PT & R
    Beek, 6191 JW, Netherlands
  • Franciscus Gasthuis
    Rotterdam, 3045 PM, Netherlands
  • Albert SchweitzerZiekenhuis
    Zwijndrecht, 3331 LZ, Netherlands
  • Optimal Clinical Trials
    Auckland, 1010, New Zealand
  • P3 Research
    Newtown Wellington NZ, 6021, New Zealand
  • Salvia Lekston I Madej Sp. J.
    Katowice, 40772, Poland
  • Metabolic Health Center Pawel Bogdanski
    Poznan, 60592, Poland
  • Ladulaas Kliniska Studier
    Borås, 506 30, Sweden
  • Forskningsenheten Carlanderska
    Göteborg, 40545, Sweden
  • Akademiska sjukhuset
    Uppsala, 751 85, Sweden
  • Waterloo Medical Centre
    Blackpool, FY4 3AD, United Kingdom
  • Clifton Medical Centre, Rotherham
    Rotherham, S65 1DA, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Sep 2022, 18 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion. A results delay was requested in Aug 2023.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 18 months is above that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2020
First posted
Dec 14, 2020
StartActual
Mar 8, 2021
Primary completionActual
Sep 15, 2022
CompletionActual
Oct 7, 2022
Results delay requested
Aug 2, 2023
Results first posted
Nov 2, 2023
Last update
Nov 2, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 2, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04667377
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Mar 8, 2021
Primary completion
Sep 15, 2022
Completion
Oct 7, 2022
Results posted
Nov 2, 2023
Last update
Nov 2, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion